-
‘I wouldn’t dare take these drugs’: how China supplies untested peptides to the west
The success of weight-loss drugs has driven demand for injectable compounds that claim to improve everything from sleep to skin.
-
PMCPA rules AstraZeneca UK responsible for employee’s social media activity
An employee clicking “like” on a third-party LinkedIn post was found to be a breach of seven clauses of the ABPI Code.
-
House Appropriations Committee releases bipartisan healthcare plan
The House proposal notably omits some key items recently announced in President Trump’s healthcare plan.
-
DOJ secures record-breaking $6.8 billion in False Claims Act settlements, judgments for FY 2025
The healthcare fraud category took the lion’s share with a staggering $5.7 billion in recovered funds from FCA matters.
-
Amid calls of political favoritism, FDA continues to award national priority drug vouchers
In addition to questions from members of Congress, the program is facing scrutiny from medical organizations over whether it’s putting politics before science.
-
Injunction halts change to long-standing safety-net drug-pricing program
Under HHS’s rebate model program, safety-net providers would have to pay millions upfront for drugs that would otherwise be spent on low-income patients.
-
Third‑party disclosure: a practical guide for pharmaceutical compliance and risk teams
Principal third-party disclosure mechanisms and the common pitfalls for pharmaceutical compliance and risk teams.
-
A transformational 2025 in US healthcare – and more to come in 2026
In many ways, 2025 found the healthcare sector at a crossroads, with compliance officers holding their heads.